This paper is in the following e-collection/theme issue:

mHealth for Treatment Adherence (404) Mobile Health (mhealth) (2982) Mobile Health in Psychiatry (438) Psychotic Disorders (162)

Published on in Vol 5, No 2 (2017): February

Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia

Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia

Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia

Authors of this article:

Earle E Bain1 Author Orcid Image ;   Laura Shafner2 Author Orcid Image ;   David P Walling3 Author Orcid Image ;   Ahmed A Othman1 Author Orcid Image ;   Christy Chuang-Stein4 Author Orcid Image ;   John Hinkle5 Author Orcid Image ;   Adam Hanina2 Author Orcid Image
Article Authors Cited by (93) Tweetations (19) Metrics

Earle E Bain   1 * , MD ;   Laura Shafner   2 * , MSc ;   David P Walling   3 * , PhD ;   Ahmed A Othman   1 * , PhD ;   Christy Chuang-Stein   4 * , PhD ;   John Hinkle   5 * , PhD ;   Adam Hanina   2 * , MBA

1 AbbVie Inc., North Chicago, IL, United States

2 AiCure, LLC, New York, NY, United States

3 CNS Network, LLC, Garden Grove, CA, United States

4 Chuang-Stein Consulting, Kalamazoo, MI, United States

5 EarlyPhase Sciences, Inc., Cary, NC, United States

*all authors contributed equally

Corresponding Author: